MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for Matthew Kent´┐Ż
0.984
+0.064 (6.97%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.92 - 1.01
52 week 0.64 - 7.32
Open 1.00
Vol / Avg. 2.75M/8.42M
Mkt cap 415.70M
P/E     -
Div/yield     -
EPS -0.32
Shares 409.49M
Beta 1.41
Inst. own 26%
Feb 22, 2016
Q4 2015 Mannkind Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 3, 2016
Mannkind Corp to Discuss Company Developments Conference Call
Jan 13, 2016
Mannkind Corp at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2016
Mannkind Corp at JPMorgan Healthcare Conference
Jan 5, 2016
Mannkind Corp Announces Termination of License and Collaboration Agreement With Sanofi Conference Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -40.53% -60.75%
Return on average equity - -
Employees 287 -
CDP Score - -

Address

25134 Rye Canyon Loop Ste 300
VALENCIA, CA 91355-5031
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company's product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company's Technosphere powders are -based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Officers and directors

Alfred E. Mann Executive Chairman of the Board
Age: 90
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew Jonathan Pfeffer Chief Executive Officer, Chief Financial Officer, Director
Age: 57
Bio & Compensation  - Reuters
Rose Alinaya Chief Accounting Officer
Age: 54
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Corporate Vice President - Technical Operations, Chief Technical Officer
Age: 59
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent Kresa Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
James S. Shannon M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters